Skip to main content
FUSION ANTIBODIES PLC logo

FUSION ANTIBODIES PLC — Investor Relations & Filings

Ticker · FAB ISIN · GB00BDQZGK16 LEI · 213800KBAYRC9VOQ9V39 IL Professional, scientific and technical activities
Open in API
Filings indexed 301 across all filing types
Latest filing 2021-06-09 Regulatory Filings
Country GB United Kingdom
Listing IL FAB

About FUSION ANTIBODIES PLC

https://www.fusionantibodies.com/

Fusion Antibodies PLC is a contract research organization (CRO) that provides a comprehensive suite of services for the discovery, engineering, and supply of preclinical biologics. The company offers an integrated, end-to-end antibody development platform, spanning from initial antigen design and antibody generation to advanced engineering processes like humanization and affinity maturation. It also provides services for the supply of recombinant proteins and antibodies, including stable cell line development. Fusion Antibodies supports therapeutic and diagnostic programs, operating as a collaborative partner to guide projects through critical preclinical stages with a focus on long-term manufacturability and commercialization.

Recent filings

Filing Released Lang Actions
Price Monitoring Extension
Regulatory Filings Classification · 98% confidence The document is very short (1918 characters) and contains the header 'RNS Number : 3626B' and mentions 'RNS, the news service of the London Stock Exchange' and the 'Financial Conduct Authority'. The content itself is a brief announcement titled 'Price Monitoring Extension' regarding an auction call extension. This is a short, specific regulatory notification that does not constitute a full report (like 10-K or IR) or a standard earnings release (ER). Given the source (RNS) and the nature of the announcement (a specific market operation notice), the most appropriate classification is the general regulatory announcement category, RNS.
2021-06-09 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is identified by the header 'RNS Number' and contains a formal announcement dated May 28, 2021, regarding the 'Total Voting Rights' of Fusion Antibodies plc. This announcement explicitly states the total number of ordinary shares and voting rights (25,818,278) and notes that this figure should be used by shareholders for determining notification requirements under FCA Disclosure Guidance and Transparency Rules. This type of mandatory disclosure regarding the total number of shares, which affects shareholder voting power, is a standard regulatory filing. Since it is a specific regulatory update that doesn't fit the definitions for Director's Dealing (DIRS), Major Shareholding Notification (MRQ), or Dividend Notice (DIV), and it is a direct regulatory announcement (indicated by the RNS source and FCA reference), the most appropriate classification is the general Regulatory Filings category (RNS), as it is a routine compliance update.
2021-05-28 English
Exercise of Options and Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is identified by the 'RNS Number' header and contains a notification dated 21 May 2021 regarding the 'Exercise of Options and Total Voting Rights' by a director and employees. It details the number of new shares issued (168,334) and the resulting total voting rights (25,818,278). This type of announcement, which reports insider transactions (Director's Dealing) and resulting changes in total share capital/voting rights, is typically disseminated via regulatory news services. Since it specifically details transactions by a director (Richard Buick) and the resulting change in share capital, it strongly relates to Director's Dealing (DIRS) and Share Issue/Capital Change (SHA). However, the primary focus is the notification of insider transactions and the resulting capital change disclosure required under market abuse regulations. Given the options, 'Director's Dealing' (DIRS) is the most specific fit for the core event (exercise of options by a director), although 'Share Issue/Capital Change' (SHA) is also relevant due to the admission to trading. Since the document structure strongly resembles a standard regulatory disclosure filing (RNS format) detailing insider activity, and the transaction involves the exercise of options by a director, DIRS is a strong candidate. If DIRS is not available, SHA or RNS would be considered. Reviewing the definitions, DIRS covers 'Report of personal share transactions by company directors and executives (insider trades)'. This fits perfectly. The document is a direct report of the transaction, not an announcement of a report, so RPA/RNS fallback is not necessary unless DIRS was unavailable.
2021-05-21 English
Second Price Monitoring Extn
Share Issue/Capital Change Classification · 99% confidence The document is very short (1934 characters) and contains the header 'RNS Number : 1805Z' and mentions 'RNS, the news service of the London Stock Exchange' and 'Financial Conduct Authority'. The content describes a 'Second Price Monitoring Extension' related to trading activity, which is a specific operational announcement rather than a comprehensive financial report (like 10-K or IR) or a standard corporate action (like DIV or CAP). Since it is a direct, time-sensitive announcement distributed via the RNS system and does not fit any other specific category (like DIRS, MANG, or DIV), it falls best under the general regulatory announcement category.
2021-05-19 English
Price Monitoring Extension
Regulatory Filings Classification · 98% confidence The document is very short (1917 characters) and its primary content is an announcement regarding a 'Price Monitoring Extension' for a security, referencing the 'National Storage Mechanism' and 'RNS Number'. It explicitly states that the information is provided by RNS, the news service of the London Stock Exchange, which is approved by the Financial Conduct Authority (FCA) to act as a Primary Information Provider. This structure—a brief, time-sensitive update disseminated via the RNS system—fits the definition of a general regulatory announcement that doesn't fit a more specific financial report category. Therefore, it should be classified as a Regulatory Filing (RNS).
2021-05-19 English
Exercise of options
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is identified by the 'RNS Number' header and contains an announcement dated May 5, 2021, regarding the 'Exercise of Options and Total Voting Rights'. Specifically, it announces the issuance of new ordinary shares due to option exercises and updates the total voting rights figure post-admission. This type of announcement, which reports on changes in share capital structure or insider transactions, fits best under the 'Director's Dealing' (DIRS) or 'Share Issue/Capital Change' (SHA) categories. Since the primary focus is the issuance of new shares following option exercises and the resulting change in total voting rights, 'SHA' (Share Issue/Capital Change) is the most precise fit. However, the document is distributed via RNS and is a standard regulatory announcement. Given the options, 'SHA' covers the core event (issuance of new shares). If the document were purely about insider trading, DIRS would apply. Since it's a formal announcement of a share issuance, SHA is appropriate. Alternatively, as a general regulatory news service release, RNS could be used, but SHA is more specific to the content. Revisiting the definitions: SHA is 'Announcement regarding new share issues, stock splits, or other capital changes.' This perfectly describes the issuance of 39,585 new ordinary shares. The document is a full announcement, not just a notice that a report is attached, so RPA/RNS fallback is less preferred than the specific content classification.
2021-05-05 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.